Peter_Shapland

Peter Shapland PhD

Scientific Leader, R&D Medicinal Science and Technology, GSK Stevenage

Development chemist with wide experience of route scouting and process design with particular interest in applying Physical Organic Chemistry concepts to aid optimal process development enabling rapid scale-up of commercially viable chemical processes. Current activities include development of continuous processes to provide enhanced delivery of existing medicines. I have experience of inhaled medicine manufacture and analysis along with experience of "more typical" tablet and capsule medicine research and development and Regulatory submission compilation providing a rounded experience of primary and secondary manufacturing in the pharmaceutical arena.


Appearances

  • Thumbnail for Emerging Technologies
    Date
    June 24, 2020
    Emerging Technologies The session brings together industrial case studies from practitioners who have delivered innovative solutions to enable the adoption of continuous processing within their companies…

    Moderator

    Speaker Image for Malcolm Berry
    Continuous Chemistry Team Manager, MB Chemistry Consulting, Ltd.

    Speakers

    Speaker Image for Moiz Diwan
    Director, Pharmaceutical Development Research & Development, AbbVie
    Speaker Image for Martin Johnson
    VP - Engineering, Synthetic Molecule Design and Development, Eli Lilly
    Speaker Image for Peter Shapland
    Scientific Leader, R&D Medicinal Science and Technology, GSK Stevenage